XML 22 R4.htm IDEA: XBRL DOCUMENT v3.24.3
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
12 Months Ended
Aug. 31, 2024
Aug. 31, 2023
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS    
Revenue $ 464,278 $ 226,208
Cost of goods sold 4,822 31,500
Gross profit 459,456 194,708
Operating expenses    
Research and development 2,360,565 3,666,721
General and administrative 3,852,021 3,062,009
Total operating expenses 6,212,586 6,728,730
Loss from operations (5,753,130) (6,534,022)
Other income (loss)    
Interest income 14,311 43,190
Unrealized loss on marketable securities (69,835) (221,693)
Total other income (loss) (55,524) (178,503)
Net loss (5,808,654) (6,712,525)
Less: Net loss attributable to non-controlling interest (13,309) (47,626)
Net loss attributable to Lexaria shareholders (5,795,345) (6,664,899)
Other comprehensive income    
Foreign currency translation adjustment (19,816) 0
Total comprehensive loss $ (5,815,161) $ (6,664,899)
Basic and diluted loss per share $ (0.47) $ (1.01)
Weighted average number of common shares outstanding    
- Basic and diluted 12,383,974 6,614,066